The present invention includes a synthetic collagen that facilitates adhesion prevention and methods of use thereof. The present invention includes a prokaryotic collagen that facilitates adhesion prevention and treatment and methods of use thereof. The prokaryotic collagen includes an isolated and purified triple helical backbone protein that facilitates adhesion prevention: one or more alteration in a triple helical backbone protein sequence, and one or more binding motifs, wherein the isolated and purified triple helical backbone protein facilitates adhesion prevention.

The present disclosure relates to a drug-eluting suture comprising an elongate strand formed of a polymer matrix. The suture includes an anti-inflammatory agent, such as tacrolimus, dispersed within the polymer matrix at a concentration ranging from 0.1% wt. to 5% wt., based on the total weight of the suture. The suture exhibits a porosity ranging from 1% to 20%. Under physiological conditions, the suture can demonstrate a mean anti-inflammatory agent release rate ranging from 0.1 ng/day to 100 ng/day for a period of at least 10 days.

This invention provides a kit for making an adhesive and/or a sealant which includes: a first composition of alginate and a multivalent cation salt at a concentration ratio (mg/ml) of 30:1 to 1:60, and a second composition of alginate and a buffer, wherein the buffer has a pH value of between 2 to 7. The invention also provides a method for making a sealant or an adhesive, by contacting the first composition and the second composition.

Methods are provided to produce optimal fractionations of charged keratins that have superior biomedical activity. Also provided are medical implants coated with these keratin preparations. Further provided are methods of treating blood coagulation in a patient in need thereof.

Intraperitoneal administration of glutamine to reduce adhesions in the peritoneum of a patient.

The inventive subject matter provides compositions and methods for transiently or permanently treating or managing an injury. Contemplated compositions are polymerizable in situ over short time periods, even in the presence of blood, without undue exothermic heat. Contemplated compositions may further comprise an anesthetic, an antiseptic, an adhesion promoter, and/or a vasoconstrictor.

Methods are provided to produce optimal fractionations of charged keratins that have superior biomedical activity. Also provided are medical implants coated with these keratin preparations. Further provided are methods of treating blood coagulation in a patient in need thereof.

Absorbable iron-based alloy implanted medical device and manufacturing method thereof. The iron-based alloy implanted medical device comprises an iron-based alloy substrate (11), a degradable polymer layer (13) disposed on a surface of the iron-based alloy substrate (11), and a tannic acid chemical conversion film (12) disposed on a surface of the iron-based alloy substrate (11). After the medical device is implanted into a body, the tannic acid chemical conversion film (12) is configured to protect the iron-based alloy substrate (11) coated thereby from being in contact with a body fluid, thereby ensuring that the device meets a clinical mechanical property requirement in the early stage of implantation. Furthermore, the iron-based alloy implanted medical device has a decreased size, and produces a decreased amount of a corrosive product after being implanted, facilitating faster absorption or elimination of the corrosive product.

Provided are a temperature sensitive adhesion prevention composition and a method for producing the same, the composition comprising a polyethylene oxide (PEO) containing copolymer, a carboxy polysaccharide, and a monovalent cation.

A method of conferring modified properties, e.g. modified physical and/or biochemical properties, to a metallic substrate surface, including at least two steps being (i) a first step including at least exposing the substrate surface to a hetero-bifunctional anchoring molecule carrying at least a silane group and at least a A.sub.1 group, the A.sub.1 group being optionally introduced within the anchoring molecule via a preliminary functionalizing step, and (ii) a second step of exposing the substrate surface to a polymer carrying at least three groups A.sub.2 capable of reacting with A.sub.1 in a thiol-ene reaction, the number average molecular weight of the polymer being greater than 1 000 g/mol.